Last reviewed · How we verify

Vaso-occlusive crisis in sickle cell disease — Treatment Landscape & Competitive Intelligence

Vaso-occlusive crisis in sickle cell disease (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Vaso-occlusive crisis in sickle cell disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Selg1 CRIZANLIZUMAB Novartis Selectin Blocker [EPC] P-selectin 2019-01-01
ADAKVEO CRIZANLIZUMAB-TMCA NOVARTIS PHARMS CORP Selectin Blocker [EPC] P-selectin

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. NOVARTIS PHARMS CORP · 1 drug in Vaso-occlusive crisis in sickle cell disease
  2. Novartis · 1 drug in Vaso-occlusive crisis in sickle cell disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Vaso-occlusive crisis in sickle cell disease:

Cite this brief

Drug Landscape (2026). Vaso-occlusive crisis in sickle cell disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/vaso-occlusive-crisis-in-sickle-cell-disease. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing